Home›Companies›Nxtcure Labs
Nxtcure Labs

Engineering the future of Cancer Drug Discovery

NxtCure Labs is an AI-native, full-stack CRO built to take therapeutics from discovery to market faster. We are reinventing medicine from lab to drug discovery. About 2 million Americans are diagnosed with cancer every year. Science has never moved faster, new immunotherapies, targeted drugs and cancer vaccines arrive every year. But roughly 90% of cancer drugs fail in clinical trials, and about 80% of trials run late. The breakthroughs exist. The way we test them is stuck in the last century. NxtCure is building autonomous clinical trials. Before a single patient enrolls, we run the trial thousands of times on digital twins. Each virtual patient is a system of coupled differential equations that track how a drug moves through plasma, tumor and heart, and how the tumor grows, shrinks or fights back. The parameters are fit to real trial data, so every twin behaves like real biology. Across thousands of simulations we can calculate the odds that a dose will hit its endpoints, and fix the protocol before it costs anyone time, money or hope. Then 13 AI agents run the trial. Each one owns a stage: drafting the protocol, ranking sites, pre-screening patients, forecasting drug supply, watching for adverse events, predicting dropout, cleaning data and writing the final report. As real data comes in, the twins update and flag problems weeks before a human would see them. In 2025, the FDA laid out how computer simulation can take its place. Soon a cancer drug will run through thousands of simulated trials before it ever touches a lab, and reach patients years faster. We’re building that future.
Active Founders
Alessandro Hammond, Founder & CEO of Nxtcure Labs (YC F26), engineering the future of cancer drug discovery. Harvard '25 (Computational Biology), Phi Beta Kappa. Schwarzman Scholar (Tsinghua). MD/PhD at Yale.
Company Launches
NxtCure Labs - The full-stack AI CRO Oncology
See original launch post

Alessandro Hammond is a Stage III cancer survivor. On January 15, 2026, Alessandro went in for an innocuous lump, which turned out to be an aggressive tumor. Alessandro was rushed into emergency surgery. He used an early version of NxtCure to find a clinical trial that changed his treatment trajectory. He immediately underwent several rounds of chemotherapy (3x BEP). Now a Harvard and Yale MD-PhD cancer researcher, he founded NxtCure Labs to get the next generation of cancer drugs to patients faster.

https://youtu.be/STuKsvvP460

Promising oncology drugs are being developed faster than ever, but testing them and getting FDA approval is the bottleneck. Cancer drug trials take over a decade, and only about 3% of cancer drugs that enter human trials are ever approved.

NxtCure is building digital twins for cancer drug development, from the animal study to the clinical trial:

  • Digital twins: simulated versions of oncology model organisms that predict tumor response and drug exposure, so biotechs can choose doses and design studies before running them.
  • Protocol simulation: each twin is a system of coupled differential equations that tracks how a drug moves through plasma and tumor. Thousands of virtual patients estimate the odds a dosing plan will hit its endpoints before the first patient enrolls.
  • Continuous monitoring: the digital twins are trained in real-time throughout the study and flag endpoints that are at risk before they’re missed.

Alongside the twins, AI agents take on routine trial work such as site selection, patient pre-screening, safety monitoring and data cleaning, and every critical call goes to a physician expert.

NxtCure Labs is looking to connect with preclinical and clinical-stage biotechs to run their trials, or CROs that are interested in licensing our digital twins.

Website and Demo: https://nxtcure.com

Contact: Superadmin@nxtcure.com

Book A Demo: https://calendly.com/superadmin-nxtcure/nxtcure-labs-demo

Nxtcure Labs
Founded:2026
Batch:Fall 2026
Status:
Active
Location:San Francisco
Primary Partner:Aaron Epstein